Opportunities for collective wisdom in stroke research

Cerebrovascular Diseases

Volumn 7, Issue 6, 1997, Pages 313-314

  Moskowitz, Michael A ^a   Dalkara, Turgay ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Maryland Medical Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

BRAIN ISCHEMIA; DRUG DEVELOPMENT; EDITORIAL; MEDICAL RESEARCH; PRIORITY JOURNAL; STROKE;

EID: 0030728440     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000108212     Document Type: Article

References (7)

1. Hossman KA, Zimmermann V: Resuscitation of the monkey brain after I h complete ischemia. I. Physiological and morphological observations. Brain Res 1974:8:59-74.
2. Astrup J, Siesjo B, Lindsay S: Thresholds in cerebral ischemia: The ischemic penumbra. Stroke 1981;12:723-725.
3. Koroshetz VVJ, Moskowitz MA: Emerging treatment for stroke in humans. Trends Pharmacol Sci 1996;17:227-233.
4. Heiss WD: PET evidence bearing on the therapeutic window; in Moskowitz MA. Caplan LR (cds): Cerebrovascular Diseases. 19th Princeton Stroke Conf. Newton, Bulierworth Heine-mann, 1995, pp 371-378.
5. Ginsberg MD: The concept of the therapeutic window: A synthesis of critical issues; in Moskowitz MA. Caplan LR (cds): Cerebrovascular Diseases. 19th Princeton Stroke Conf. Newton. Bulierworth Hcincmann. 1995. pp 331-352.
6. Welch KMA, Windham J, Knight RA. Nagesh V, Hugg JW, Jacobs M, Peck D, Booker P, Dereski MO, Levine SR: A model to predict histo-pathology of human stroke using diffusion and T2-weighted magnetic resonance imaging. Stroke 1995:26:1983-1989.
7. Hara H, Friedlander RM, Gagliardini V, Avata C, Fink K, Huang Z, Shimizu-Sasamata M, Yuan J, Moskowitz MA: Inhibition of interleukin 1β converting enzyme family proteascs reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci USA 1997:94: 2007-2012